ImmunoMet Therapeutics is a clinical stage biotechnology company based in Houston, Texas that focuses on developing novel therapies for oncology and fibrosis by targeting cellular metabolism.
The company has successfully completed a Phase 1 study in healthy volunteers and has announced the initiation of a Phase 1b trial for IM156 in pancreatic cancer, demonstrating their commitment to advancing innovative treatments in the field of oncology.
Generated from the website